PT - JOURNAL ARTICLE AU - Tabibzadeh, Nahid AU - Vidal-Petiot, Emmanuelle AU - Cheddani, Lynda AU - Haymann, Jean-Philippe AU - Lefevre, Guillaume AU - Etain, Bruno AU - Bellivier, Frank AU - Marlinge, Emeline AU - Delavest, Marine AU - Vrtovsnik, François AU - Flamant, Martin TI - Chronic lithium therapy and urine concentrating ability in individuals with bipolar disorder: association between daily dose and resistance to vasopressin and polyuria AID - 10.1101/2022.01.28.22270045 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.28.22270045 4099 - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22270045.short 4100 - http://medrxiv.org/content/early/2022/01/30/2022.01.28.22270045.full AB - Background and objectives Chronic lithium treatment in individuals with bipolar disorder can induce nephrogenic diabetes insipidus. However, the prevalence, kinetics and mechanisms of such complication are poorly known. We aimed at evaluating patterns of urine concentrating ability and the correlates of 24-hour urine output in individuals treated with lithium.Design, setting, participants and measurements Prospective single center observational study of 217 consecutive individuals treated with lithium carbonate and referred to the renal unit. All individuals collected 24-hour urine the day before admission and underwent a desmopressin (DDAVP) concentrating test, fasting plasma vasopressin measurement (copeptin measurement in a subset of individuals, n=119), and measured GFR (mGFR) using urinary 99Tc-DTPA clearance. Maximal urine osmolality (Max Uosm) was defined as the highest level during the DDAVP test.Results 21% of individuals displayed polyuria (> 3l/day), but 55% displayed elevated fasting vasopressin level (> 5 pg/ml). During the DDAVP test, Uosm was significantly lower, and urinary output and free water clearance were significantly higher in the highest treatment duration tertile (> 10 years) whereas no difference was observed between the first two tertiles (< 2.5 years and 2.5-10 years). Among individuals with normal Max Uosm (>600 mOsm/KgH2O) (n=128), 51% displayed elevated vasopressin levels, which was associated with higher lithium daily doses (950 [750- 1200] versus 800 [500- 1000] mg/d, p<0.001), and 100% of patients with lithium daily dose ≥1400 mg/d had high vasopressin levels. In multivariable analysis, 24-hour urine output was associated with higher lithium daily dose (β 0.49 ± 0.17, p=0.005), female sex (β -359 ± 123, p=0.004), daily osmolar intake (β 2.21 ± 0.24, p<0.001), maximal urine osmolality (β -2.89 ± 0.35, p<0.001) and plasma vasopressin level (β 10.17 ± 4.76, p=0.03), but not with lithium formulation.Conclusions Higher lithium daily dose was associated with higher vasopressin levels and higher urine output, independently of other factors. Daily osmolar intake was also associated with higher 24-hour urine output. These results suggest that controlled salt and protein intake and lithium dose might reduce renal resistance to vasopressin in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly funded by a research grant from the SFNDT (Societe Francophone de Nephrologie, Dialyse et Transplantation).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of APHP.Nord gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors